COSTA MESA, Calif.--(BUSINESS WIRE)--Valeant Pharmaceuticals International (NYSE:VRX) today announced that its board of directors has concluded that as a result of errors in the company’s accounting for stock options, financial statements for certain prior periods will need to be restated.
